Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
14.20
-0.02 (-0.14%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.13 - 14.51
52 week 11.25 - 19.62
Open 14.25
Vol / Avg. 889,023.00/1.11M
Mkt cap 1.48B
P/E     -
Div/yield     -
EPS -1.36
Shares 104.32M
Beta 0.56
Inst. own 108%
Feb 27, 2017
Q4 2016 Lexicon Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -140.73% -169.71%
Operating margin -136.00% -164.58%
EBITD margin - -162.11%
Return on average assets -26.20% -25.09%
Return on average equity -75.91% -63.81%
Employees 168 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 51
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and Supply Operations
Age: 62
Bio & Compensation  - Reuters
Praveen Tyle Ph.D. Executive Vice President of Research and Development
Age: 56
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 56
Bio & Compensation  - Reuters
Gary Branch Vice President - Sales
Bio & Compensation  - Reuters
Kiernan Seth Ph.D. Vice President - Marketing
Bio & Compensation  - Reuters
Alexander A Santini Chief Commercial Officer
Bio & Compensation  - Reuters